The Next Frontier in Pancreatic Cancer: Targeting the Tumor Immune Milieu and Molecular Pathways

SIMPLE SUMMARY: Pancreatic ductal adenocarcinoma (PDAC) has a notoriously bad prognosis due to its high mortality and lack of good therapies. Chemotherapy is the current standard of treatment for PDAC, yet survival for most PDAC remain at around one year. Better therapeutic options are in dire need....

Descripción completa

Detalles Bibliográficos
Autores principales: Yin, Chao, Alqahtani, Ali, Noel, Marcus S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9179513/
https://www.ncbi.nlm.nih.gov/pubmed/35681599
http://dx.doi.org/10.3390/cancers14112619

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9179513/
https://www.ncbi.nlm.nih.gov/pubmed/35681599
http://dx.doi.org/10.3390/cancers14112619

Ejemplares similares